Diseases
L2 Bio, the leader in adipose-derived stem cell banking, is actively recruiting Principal Investigators for its recently FDA-approved Phase 2B clinical trial for Crohn's Disease. This study aims to investigate a novel intravenous delivery of adipose-derived stem cells (ADSCs) for the treatment of Crohn's Disease. The
Diseases
The Red Meat Abattoir Association (RMAA) has sounded the alarm on the severe impacts of the foot-and-mouth disease (FMD) outbreak on the country's red meat industry, warning of traceability, biosecurity, and vaccine availability gaps that could undermine the sector's credibility and long-term growth. Agriculture Minister John
Diseases
The South African government and the Red Meat Abattoir Association (RMAA) are facing a worsening foot-and-mouth disease (FMD) outbreak, which has disrupted economic activity and trade. The FMD outbreak has exposed weaknesses in the country's disease control and biosecurity measures, and the RMAA is urging stronger cooperation between
Diseases
Research conducted by a team from Kharkiv National Medical University has found a significant rise in hypertension and related cardiovascular complications, such as acute myocardial infarction and stroke, among the adult population of Kharkiv during the armed conflict in 2022-2023. The study used data from the Information and Analytical Center
Diseases
Research from Imperial College London has shed light on the complex process of recovery from chronic obstructive pulmonary disease (COPD) exacerbations. The study, published in the American Journal of Respiratory and Critical Care Medicine, found that resolution of airway inflammation is a critical step in the recovery process, driven by
Diseases
Researchers from Southern Medical University have published a new report on the application of salivary metabolomics in diagnosing, monitoring, and managing oral diseases. According to the study, salivary metabolomics represents a powerful non-invasive approach for identifying disease-specific biomarkers and understanding the underlying pathophysiological processes. The researchers note that while this
Diseases
Research has made significant progress in understanding the role of the gut microbiome in Parkinson's disease, a progressive and common neurodegenerative condition. A large-scale meta-analysis of nearly 4,500 Parkinson's disease patients' samples has revealed significant gut microbiome alterations. Researchers used machine learning to identify
Diseases
Merry Life Biomedical Company has announced the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). The multicenter trial will enroll 210 patients with mild cognitive impairment (MCI) or mild dementia across the United States, Sweden,
Diseases
District veterinarians in Australia have been intensifying their preparation for a potential foot and mouth disease (FMD) outbreak by participating in a hands-on training course in Kenya. The training, led by the European Commission, brought together about 15 veterinary professionals from across the world to learn from farmers and field
Diseases
The Alzheimer's disease pipeline is rapidly evolving, with 200+ key pharma companies actively working on therapeutic candidates for the treatment of Alzheimer's disease. A recent report by DelveInsight highlights the comprehensive pipeline landscape, including 220+ pipeline drugs in various stages of development. The pipeline report provides
Diseases
Capstan Therapeutics, a clinical-stage biotechnology company, has successfully dosed the first participants in its Phase 1 trial of CPTX2309, a targeted lipid nanoparticle that delivers an anti-CD19 CAR mRNA preferentially to CD8-expressing cytotoxic T cells. The trial aims to evaluate the safety, tolerability, and pharmacodynamic activity of CPTX2309 in healthy
Diseases
Capsida Biotherapeutics, a clinical-stage genetic medicines company, has announced the clearance of the Investigational New Drug (IND) application for CAP-003, a potential best-in-class intravenously administered gene therapy, to enter clinical trials for Parkinson's disease associated with GBA mutations (PD-GBA). This milestone marks the second wholly owned clinical program
